The recent global mpox outbreaks underscore the critical need for antiviral development, hindered by the complexity of the MPXV genome. Using yeast TAR cloning, CRISPR-Cas9, and Lambda Red recombination to engineer replication-defective MPXV, the authors offer a platform for therapeutic research and identify G243-1720, a compound with a tecovirimat-like mechanism, as a promising anti-poxvirus compound.
- Jiannan Chen
- Liyuan Hu
- Rong Zhang